|
Gene: OLFML2A |
Gene summary for OLFML2A |
Gene summary. |
Gene information | Species | Human | Gene symbol | OLFML2A | Gene ID | 169611 |
Gene name | olfactomedin like 2A | |
Gene Alias | PRO34319 | |
Cytomap | 9q33.3 | |
Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q68BL7 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
169611 | OLFML2A | P47T-E | Human | Esophagus | ESCC | 6.46e-08 | 1.32e-01 | 0.1067 |
169611 | OLFML2A | P48T-E | Human | Esophagus | ESCC | 4.78e-04 | 1.39e-01 | 0.0959 |
169611 | OLFML2A | P52T-E | Human | Esophagus | ESCC | 1.27e-09 | 2.29e-01 | 0.1555 |
169611 | OLFML2A | P61T-E | Human | Esophagus | ESCC | 2.08e-13 | 3.62e-01 | 0.099 |
169611 | OLFML2A | P62T-E | Human | Esophagus | ESCC | 1.38e-04 | 1.26e-01 | 0.1302 |
169611 | OLFML2A | P65T-E | Human | Esophagus | ESCC | 2.85e-06 | 1.65e-01 | 0.0978 |
169611 | OLFML2A | P74T-E | Human | Esophagus | ESCC | 7.19e-11 | 3.50e-01 | 0.1479 |
169611 | OLFML2A | P75T-E | Human | Esophagus | ESCC | 1.55e-02 | 1.31e-01 | 0.1125 |
169611 | OLFML2A | P76T-E | Human | Esophagus | ESCC | 2.00e-02 | 1.25e-02 | 0.1207 |
169611 | OLFML2A | P80T-E | Human | Esophagus | ESCC | 4.01e-02 | 2.16e-01 | 0.155 |
169611 | OLFML2A | P82T-E | Human | Esophagus | ESCC | 9.02e-06 | 6.02e-01 | 0.1072 |
169611 | OLFML2A | P83T-E | Human | Esophagus | ESCC | 3.52e-07 | 2.18e-01 | 0.1738 |
169611 | OLFML2A | P84T-E | Human | Esophagus | ESCC | 6.92e-03 | 3.20e-01 | 0.0933 |
169611 | OLFML2A | P107T-E | Human | Esophagus | ESCC | 6.15e-28 | 7.35e-01 | 0.171 |
169611 | OLFML2A | P130T-E | Human | Esophagus | ESCC | 8.04e-27 | 6.32e-01 | 0.1676 |
169611 | OLFML2A | C04 | Human | Oral cavity | OSCC | 6.19e-04 | 4.12e-01 | 0.2633 |
169611 | OLFML2A | C30 | Human | Oral cavity | OSCC | 4.51e-33 | 1.81e+00 | 0.3055 |
169611 | OLFML2A | C51 | Human | Oral cavity | OSCC | 4.29e-05 | 5.46e-01 | 0.2674 |
169611 | OLFML2A | LP15 | Human | Oral cavity | LP | 2.40e-02 | 7.00e-01 | 0.2174 |
169611 | OLFML2A | SYSMH1 | Human | Oral cavity | OSCC | 2.64e-20 | 6.31e-01 | 0.1127 |
Page: 1 2 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00301984 | Esophagus | ESCC | extracellular matrix organization | 171/8552 | 301/18723 | 6.08e-05 | 4.67e-04 | 171 |
GO:00430624 | Esophagus | ESCC | extracellular structure organization | 171/8552 | 302/18723 | 7.73e-05 | 5.76e-04 | 171 |
GO:00452294 | Esophagus | ESCC | external encapsulating structure organization | 172/8552 | 304/18723 | 7.80e-05 | 5.80e-04 | 172 |
GO:00301983 | Oral cavity | OSCC | extracellular matrix organization | 146/7305 | 301/18723 | 4.67e-04 | 2.77e-03 | 146 |
GO:00452293 | Oral cavity | OSCC | external encapsulating structure organization | 147/7305 | 304/18723 | 5.30e-04 | 3.08e-03 | 147 |
GO:00430623 | Oral cavity | OSCC | extracellular structure organization | 146/7305 | 302/18723 | 5.59e-04 | 3.23e-03 | 146 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
OLFML2A | SNV | Missense_Mutation | c.1423N>A | p.Ala475Thr | p.A475T | Q68BL7 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
OLFML2A | SNV | Missense_Mutation | c.1522N>A | p.Glu508Lys | p.E508K | Q68BL7 | protein_coding | deleterious(0.01) | benign(0.038) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
OLFML2A | SNV | Missense_Mutation | rs199680116 | c.1762N>A | p.Val588Met | p.V588M | Q68BL7 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AC-A5XU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | letrozole | SD |
OLFML2A | SNV | Missense_Mutation | c.831N>T | p.Lys277Asn | p.K277N | Q68BL7 | protein_coding | deleterious(0.01) | possibly_damaging(0.478) | TCGA-E2-A1B4-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | arimidex | SD | |
OLFML2A | insertion | Frame_Shift_Ins | rs769664558 | c.1208_1209insC | p.Val406CysfsTer51 | p.V406Cfs*51 | Q68BL7 | protein_coding | TCGA-BH-A0BP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
OLFML2A | SNV | Missense_Mutation | novel | c.1747N>T | p.Gly583Cys | p.G583C | Q68BL7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
OLFML2A | SNV | Missense_Mutation | rs777350219 | c.1211C>T | p.Pro404Leu | p.P404L | Q68BL7 | protein_coding | tolerated(0.14) | benign(0.021) | TCGA-C5-A1BN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
OLFML2A | SNV | Missense_Mutation | c.1636N>A | p.Glu546Lys | p.E546K | Q68BL7 | protein_coding | deleterious(0) | possibly_damaging(0.678) | TCGA-VS-A8QA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
OLFML2A | SNV | Missense_Mutation | novel | c.554C>G | p.Ser185Cys | p.S185C | Q68BL7 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-ZJ-A8QR-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
OLFML2A | SNV | Missense_Mutation | rs368549348 | c.1573N>A | p.Val525Met | p.V525M | Q68BL7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A6-2680-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |